Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Heart Rhythm Society 2019 Scientific Sessions (HRS)
May 08 - 11, 2019; San Francisco, California
May 08 - 11, 2019San Francisco, California
HRS 2019Substernal-Lead ICD May Be 'Inflection Point' in ICD Evolution Some see the future in the device, functional as a standard implantable defibrillator but with a high-voltage lead that fits between the sternum and heart and no transvenous leads to ever extract.
Medscape Medical News, May 15, 2019
HRS 2019CRT Can Reverse HF From Cancer Chemotherapy: MADIT-CHICAdded to heart failure meds, the pacing therapy can improve symptoms and reverse ventricular damage from chemotherapy in a group sometimes overlooked for proven treatments, says a prospective study.
Medscape Medical News, May 14, 2019
HRS 2019AF Ablation, Renal Denervation a Promising Team in ERADICATE-AFPatients getting both procedures instead of AF ablation alone had less atrial fib over 1 year. Researchers are upbeat about the combination, others point to study limitations and other cautions.
Should ICDs in Primary Prevention Go the Way of Aspirin?Do historic recommendations on ICD use for primary prevention in patients with ischemic heart failure still hold as background
therapies and the patient population evolve, asks John Mandrola, MD.
We Still Need a Sham-Controlled Trial for AF AblationCatheter ablation for atrial fibrillation has yet to be put to the ultimate test of a sham-controlled trial. John Mandrola,
MD, makes the case for doing one now.
From Medical Skeptic to Researcher: The View From the Other SideCritiquing studies is all very well until you’re one of the co-authors. John Mandrola, MD feels the heady joy of having a
late-breaking clinical trial at a major meeting and the temptation to ‘spin’.
Popular News from HRS 2018
CABANA: Ablation Disappoints for AF vs Drugs, Questions RemainCatheter ablation for atrial fibrillation didn't cut clinical risk better than did rate- or rhythm-control drugs in a widely
anticipated randomized trial. But some saw enticing, useful messages in the data.
Strokes From Clot on Watchman LAA Closure Device: OAC InsightsThe risks for ischemic and hemorrhagic stroke climbed whenever thrombus was seen on the implanted left atrial appendage occluder,
often after oral anticoagulants were halted, in a pooled analysis.
